Common Antidepressant Eases Long COVID Fatigue in 399 Adults

For the 65 million people worldwide battling long COVID, crushing fatigue has been one of the most devastating symptoms with almost no proven treatments available until now.

A major clinical trial has found that fluvoxamine, an inexpensive antidepressant already used for depression and anxiety, significantly reduces fatigue and improves quality of life in long COVID patients. The study involved 399 adults in Brazil who had experienced persistent exhaustion for at least 90 days after their COVID infection.

Researchers from McMaster University, Stanford, Duke, and several Brazilian institutions worked together on the trial. They wanted to test whether two existing, affordable medications could help patients who had been desperate for evidence-based options.

Participants received either fluvoxamine (sold as Luvox), metformin (a diabetes drug), or a placebo for 60 days. The results were striking: fluvoxamine performed dramatically better than the placebo, with statistical analysis showing a 99 percent probability that the medication was genuinely effective.

People taking fluvoxamine reported not just less fatigue but real gains in their overall quality of life across multiple measures. For many, this could mean the difference between being able to work, care for their families, and participate in everyday activities again.

Interestingly, metformin didn't produce the same benefits. While earlier research showed it might prevent long COVID if taken during the initial infection, it provided no meaningful improvement for people already experiencing established fatigue.

The Bright Side

What makes this discovery particularly hopeful is that fluvoxamine is already widely available and well understood by doctors. It's inexpensive and doesn't require new manufacturing or lengthy approval processes.

The trial used an innovative adaptive design that allowed researchers to reach reliable conclusions more efficiently than traditional studies. This meant they could stop testing once the evidence became clear enough, getting answers to patients faster while maintaining scientific rigor.

The researchers are careful to note that fluvoxamine isn't a complete cure for long COVID, which involves many different symptoms and biological processes. But for the debilitating fatigue that has stolen so many people's quality of life, this medication offers the first clinically proven relief.

Additional studies will help determine which patients benefit most and whether fluvoxamine could work alongside other developing treatments. But for now, doctors finally have strong evidence for something they can offer patients today, not years from now.

After years of uncertainty and few treatment options, this breakthrough brings real hope to millions struggling to reclaim their energy and their lives.